PHA/RMA News

Axsome Therapeutics Q3 Revenue Surges 52% but Shares Drop on Profitability Path Concerns

Axsome Therapeutics (AXSM) reported Q3 revenue surging 52% year-on-year, driven by the commercial ramp of its Auvelity (major depressive disorder) and Sunosi (narcolepsy/hypersomnia) products.

Nov 3, 2026

Karyopharm Therapeutics Files Chapter 11 Amid Ayrmid Merger — XPOVIO Franchise Transition Under Distress

Karyopharm Therapeutics (KPTI) filed for Chapter 11 bankruptcy protection while simultaneously pursuing a merger with Ayrmid, a company focused on developing its selinexor (XPOVIO) franchise.

Nov 3, 2026

iX Biopharma Says US Defence Contract for Wafermine Not at Risk Despite Nevada Partner's Licensing Gap

iX Biopharma stated its US Department of Defense supply contract for Wafermine does not depend on Nevada partner Orion Health, which lacks the required state pharmaceutical license

Nov 3, 2026

Inovio (INO) Surges 224% on FDA Approval of Voceryq for Recurrent Respiratory Papillomatosis: First Commercial Product Validates DNA Medicine Platform

Inovio Pharmaceuticals surged 224% after FDA approved Voceryq for recurrent respiratory papillomatosis, marking the company's first commercial approval and validating its DNA medicine platform after decades of clinical development.

Nov 3, 2026

Baird Medical Signs Exclusive 19-Province China Distribution Deal with China Resources for MWA Products

Baird Medical and China Resources Pharmaceutical Commercial Group signed an exclusive distribution deal for microwave ablation products across 19 Chinese provincial markets.

Nov 2, 2026

Mold-Tek Packaging Jumps 17% as Q2 FY27 Profit Rises 35% on Pharma and FMCG Packaging Demand

Mold-Tek Packaging shares surged 17% after Q2 FY27 net profit rose 35.5% YoY to Rs 21 crore on 30.5% revenue growth

Nov 2, 2026

India Specialty Chemicals Q2 FY27: Navin Fluorine Up 57%, Acutaas Raises CDMO Target

Navin Fluorine delivered 57% revenue growth in Q2 FY27 with 34.2% EBITDA margins; Acutaas Chemicals raised its FY27 CDMO target.

Nov 2, 2026

AnaptysBio Seen as Undervalued Versus PTCT and MIRM on Royalty Stream and Legal Upside

A special situations investor has published a bullish thesis arguing AnaptysBio is undervalued relative to biotech peers PTCT and MIRM

Nov 1, 2026

Eli Lilly Stock Hits Record as Affordable Weight-Loss Drugs Unlock Broader Market

Eli Lilly shares reached a record high as the company's weight-loss drugs became more affordable and accessible to patients

Nov 1, 2026

RPG Life Sciences Targets 25% CAGR in API Business and Plans New Acquisition

RPG Life Sciences MD Ashok Nair outlined a 25% CAGR growth target for the company's active pharmaceutical ingredient business

Nov 1, 2026

US Q3 2026 Earnings: Alphabet Cloud Doubles, Eli Lilly Surges 39%, Old Dominion Beats

Alphabet posted 25% revenue growth to $127.6 billion as Google Cloud surged 103%, though negative free cash flow raised AI spending concerns.

Oct 31, 2026

Acumen Pharmaceuticals Shares Plunge 80% After Alzheimer's Clinical Trial Failure

Acumen Pharmaceuticals shares collapsed 80% after its Alzheimer's disease clinical trial failed

Oct 31, 2026

Chong Kun Dang Q3 Profit Rises 15% on Ozempic and Eylea Sales as Korea Budget Gap Widens

Korean pharma Chong Kun Dang posted Q3 operating profit up 15% year-on-year on obesity drug and eye therapy sales

Oct 31, 2026

Exelixis Reports Q3 2026 Earnings; Oncology Biotech Posts Results as Cabozantinib Franchise Matures

Exelixis (EXEL) published its Q3 2026 earnings call slide deck, releasing results from the oncology-focused biopharmaceutical company.

Oct 30, 2026

Incyte Q3 Net Loss on $1.23B Vega Charge; FY26 Sales Guidance Raised

Incyte Q3 net loss driven by $1.23B Vega acquisition charge, not operational decline Company raised FY26 sales guidance, citing commercial portfolio growth across hematology Q4 will be first clean quarter post-Vega; FDA pipeline and integration timelines are key

Oct 30, 2026

Eli Lilly Raises 2026 Sales Forecast as GLP-1 Obesity Drug Demand Surges

Eli Lilly raised its full-year 2026 sales forecast as demand for obesity and diabetes drugs continues to surge

Oct 30, 2026

US Q3 2026 Earnings: Tenable, Biogen, and Regional Banks Deliver Broad Beats

Tenable Holdings beat Q3 guidance with $276.4M revenue and 59% record Tenable One new business adoption

Oct 30, 2026

Merck Q3 EPS Beats Estimates and Company Raises Full-Year 2026 Guidance on Strong Pharmaceutical Pipeline Performance

Merck (MRK) Q3 2026 EPS beat analyst consensus estimates as the pharmaceutical giant raised full-year 2026 guidance, buying runway ahead of the 2028 Keytruda patent cliff

Oct 30, 2026

Novartis NVS Q3 2026 Earnings Call: CEO Narasimhan Spotlights Innovative Medicine Pipeline

Novartis CEO Vasant Narasimhan led the Q3 2026 earnings call on October 27 with Kisqali and Entresto as key innovative medicine performance drivers

Oct 29, 2026

GSK Q3 2026 Earnings Beat Expectations on Specialty Medicines and Vaccines Growth

GSK Q3 2026 earnings beat market expectations driven by specialty medicines including oncology and HIV therapeutics plus vaccine revenues.

Oct 29, 2026

Piramal Pharma Shares Jump 14% as Q2 Profitability Surges and FY27 Revenue Growth Outlook Raised to 20%

Piramal Pharma jumped 14% as Q2 profitability improved and the company raised FY27 revenue growth guidance to 19-20%, driven by CDMO demand strength and consumer healthcare momentum.

Oct 29, 2026

India Q2 FY27 Earnings Day: L&T, Bajaj Auto, Piramal Pharma Surge as Broad-Based Beats Emerge

India Q2 FY27 earnings season produced broad-based beats as L&T, Bajaj Auto, Maruti, SBI Life, and Piramal Pharma surged on strong results while LT Foods and Waaree declined.

Oct 29, 2026

Jubilant Ingrevia Q2 FY27: Revenue ₹1,394 Crore, PAT Surges 61%, ZettaOne Stake Acquired

Oct 28, 2026

Mankind Pharma Jumps 8% on Q2 FY27 Earnings Beat as 15 of 22 Analysts Maintain Buy Rating

Mankind Pharma shares surged approximately 8% after reporting a Q2 FY27 earnings beat that prompted 15 of 22 covering analysts to maintain Buy ratings, with only 4 recommending Sell.

Oct 28, 2026

Alnylam Pharmaceuticals RNAi Roundtable Highlights Brezosiran's Exon 1 Approach for Huntington's Disease

Alnylam Pharmaceuticals hosted an RNAi roundtable focusing on Brezosiran's exon 1 targeting strategy for Huntington's disease treatment.

Oct 27, 2026

US Measles Resurgence Exposes Public Health Weaknesses, Raising Vaccine Sector Concerns

A measles resurgence in the US is exposing structural weaknesses including declining vaccination rates and waning trust in health institutions

Oct 27, 2026

DK Luonix: Korean Pharma Dong-guk Life Science Rebrands, Pivots to MRI Drugs and CMO

Dong-guk Life Science voted to rename itself DK Luonix, following parent company DK Centellian's rebrand, as the Korean pharma group pivots from contrast agents to MRI drug development and contract manufacturing.

Oct 27, 2026

Xencor Shares Surge 31.3% Pre-Market on Biotech Optimism Ahead of Fed Decision

Xencor (XNCR) jumped 31.3% pre-market as biotech sector optimism rose ahead of the Fed decision

Oct 27, 2026

WuXi AppTec Profit Surges 62.4% to $2.87B in Nine Months; Raises Full-Year Guidance

WuXi AppTec's 9-month net profit surged 62.4% to 19.16 billion yuan ($2.87B) on strong drug services demand

Oct 26, 2026

Indian Markets Rebound Sharply as Dr. Reddy's Soars 7% on USFDA Clearance and Earnings Beat

India's Nifty 50 recovered 1.2% in afternoon trading, with Dr. Reddy's Laboratories (+7%) leading the pharma rally.

Oct 26, 2026